Industry Roundtable (Part 1)

JANSSEN'S COMMITMENT TO DIVERSITY AND INCLUSION: ENDURING CHANGE FOR TOMORROW THROUGH TODAY'S ACTIONS

Daphne Chan PhD, MHEcon has over 17 years of clinical development and medical affairs experience in the pharmaceutical industry and is currently the Head of Dermatology Medical Affairs at Janssen Immunology. She is responsible for leading a team of clinicians and scientists who conduct Phase 3/4 clinical trials designed to address unmet needs in the post-approval setting, contribute insights to inform Phase 2/3 clinical development programs of new investigational therapies, and execute other scientific initiatives to increase disease awareness and broadly communicate new data and evidence that can help inform clinical practice. Dr. Chan completed her undergraduate training in Human Biology and Toxicology and her doctoral training in Clinical Pharmacology at the University of Toronto, Canada.

INCREASING DIVERSITY IN CLINICAL TRIALS: THE ARCUTIS APPROACH

David Chu, MD, PhD, FAAD has served as Executive Director, Clinical Development, at Arcutis Biotherapeutics since January 2021. Dr. Chu earned his medical degree and immunology doctorate from UC San Francisco. He trained in dermatology at NYU, joining the faculty as Assistant Clinical Professor after residency while also completing a postdoctoral research fellowship at Rockefeller University studying stem cells of the hair follicle and epidermis. Following a transition to full-time clinical medicine, he maintained a diverse clinical practice focused on immune-mediated dermatologic disorders, including as Director of Contact Dermatitis at Scripps Clinic Medical Group in San Diego until 2019, when he entered the pharmaceutical industry, joining Janssen as Director, Clinical Development in Immunology/Dermatology.

EFFECTING CHANGE THROUGH A DIVERSITY-FOCUSED STRATEGY: THE BMS’ CLINICAL TRIAL EXPERIENCE

Sharon Hanlon is Senior Director, Clinical Trial Engagement & Enrollment at Bristol-Myers Squibb (BMS). She and her team partner with patients, caregivers, patient advocacy groups, and clinical trial sites to gather insights that, when applied to clinical trial development and recruitment efforts, create a more patient and site-friendly experience. Additionally, She and her team are responsible for driving R&Ds efforts to enhance diverse patient participation in BMS clinical trials, ensuring that our clinical trial populations reflect the patient population with the disease or condition under study. She has been at BMS for more than 20 years and has held clinical operations positions of increasing responsibility from Line Management to Project Management across multiple therapeutic areas. She is a nurse by training. Before her time in the pharmaceutical industry, she had a career as a critical care nurse, nurse educator, and research nurse coordinator at hospitals in the Philadelphia area. She received her Master of Science in Nursing from Thomas Jefferson University in Philadelphia, PA.

ADDRESSING THE DIVERSITY CHALLENGES IN DERMATOLOGY CLINICAL CARE GAPS

Lotus Mallbris, MD, PhD, IFAAD is the vice president of global immunology development and medical affairs at Eli Lilly and Company. At Lilly, she is working to improve the lives of millions of people with autoimmune diseases by furthering innovation in health care and solving problems for patients. She joined Lilly in 2015 and leads the company’s multifunctional Global Clinical Development and Global Medical Affairs teams across the dermatology, rheumatology, and gastroenterology fields. Before joining Lilly, she spent several years at Pfizer and held leadership positions within the dermatology business. Before joining the corporate world, Dr. Mallbris was a practicing physician for more than ten years, starting her career as a surgeon before transitioning to the field of dermatology. Dr. Mallbris has always been devoted to patients and found caring for them incredibly rewarding, but she recognized an opportunity to take that devotion to the next level by joining the companies working to create the innovative solutions needed to help patients worldwide. She continues to be an active member of multiple external immunology research advisory boards that focus on public health and epidemiology, bridging the external state-of-the-art research with Lilly.

ABBVIE’S DIVERSITY IN DERMATOLOGY CLINICAL TRIALS

Chudy Nduaka, DVM, PhD, DABT is the Therapeutic Area Head, for Abbvie US Medical Affairs – Dermatology. He has over 20 years of Pharmaceutical Research, Development & Medical Affairs experience. In his previous roles, he led medical teams in Gastroenterology and Dermatology with primary responsibility in executing medical strategies and tactics to ensure the safe and efficacious use of medicines for chronic inflammatory diseases. Prior to working in Medical Affairs, Dr. Nduaka worked as a global clinical lead responsible for medical management of large global clinical trials and participated in regulatory filing for different medicines in the US and EU. Dr. Nduaka has experience in FDA Advisory Committees and has helped launch several products in Rheumatology, Gastroenterology & Dermatology. Dr. Nduaka graduated from Howard University, Washington DC with a PhD in Pharmacology, a Master of Science from Tuskegee University, and a DVM from Nigeria. In his spare time, he is involved in philanthropy, helping provide educational and health care resources to communities in Africa. He also actively mentors medical and pharmacy students as well as post-doctoral fellows.